Bain Capital Public Equity Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Bain Capital Public Equity Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-210,216	Closed	-$8.63M	–	80
2018 Q4	$8.63M	Buy	+210,216	New	+$7.88M	0.81%	31
2018 Q3	–	Sell	-435	Closed	-$524K	–	82
2018 Q2	$524K	Buy	+435	New	+$19.8K	0.04%	58

Other funds holding GBT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bain Capital Public Equity Management's GBT Position: Q2 2019 in Review

Bain Capital Public Equity Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2019, closing a stake of 175,333 shares — an estimated $9.28M sold.

Bain Capital Public Equity Management first reported a position in GBT in Q2 2018 and held it in 3 quarters. The position peaked at $12.2M in Q3 2018. 223 funds tracked by Wall St. Rank hold GBT as of Q2 2019.

Bain Capital Public Equity Management reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
Bain Capital Public Equity Management sold 175,333 Global Blood Therapeutics, Inc. shares in Q2 2019, an estimated $9.28M.
Bain Capital Public Equity Management first reported a position in Global Blood Therapeutics, Inc. in Q2 2018 and held it in 3 quarters.
Bain Capital Public Equity Management's Global Blood Therapeutics, Inc. position peaked at $12.2M in Q3 2018.
223 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2019.

Based on Bain Capital Public Equity Management's 13F filing for Q2 2019.